New data analyses finds that a monthly vaginal ring containing an antiretroviral drug called dapivirine can cut women’s HIV risk by more than half and, in some, by 75 percent or more.

One of the researchers, Jared Baeten, a University of Washington professor of epidemiology, medicine and global health, presented the results Tuesday at the AIDS 2016 conference in Durban, South Africa.

Vaginal rings are flexible products that fit high up in the vagina, where they release a prophylactic drug slowly over time.  The Microbicide Trials Network is funding studies on the effectiveness of the dapivirine ring. 

Read the full release